Serum procollagen type III peptide levels in patients with acute viral hepatitis.

Serum levels of procollagen type III peptide were measured by radioimmunoassay in 76 consecutive patients with acute viral hepatitis, in order to see if this index of hepatic fibrogenesis is also predictive for the development of chronic active hepatitis in high-risk patients. Serum procollagen levels were high (from 14.2 to 109.2 ng/ml, median 33.7 ng/ml) in 74 (97%) patients and normal (from 4 to 14 ng/ml, median 9.1 ng/ml) in 2 (3%) patients. The baseline serum procollagen levels were similar in all the subgroups of patients independently of the type of hepatitis. In the 59 patients with resolving hepatitis, serum procollagen levels returned to normal values from 2 to 48 weeks (mean 15). In the 17 patients with unresolved hepatitis, procollagen levels remained within the normal limits in 6 of 7 patients with non-progressive chronic disease, while were elevated (from 17.4 to 22.2 ng/ml) in 4 of 5 patients with chronic active hepatitis. Unlike transaminase activity, which could not discriminate between benign and progressive liver disease, serum levels of procollagen helped in identifying patients with unresolved hepatitis, who were developing chronic active disease.